Consolidation among the major players is expected globally as mergers, acquisitions and strategic alliances continue across the pharmaceutical and biotechnology sectors, driven by escalating R&D costs, blockbuster drug patent expirations and a need to bolster R&D pipelines. With such high R&D costs, patent and intellectual property protection will remain an ongoing issue for the industry.
Protection of patents is one of the most important determinants of the long-term prosperity of research-orientated pharmaceutical companies.
In Malta, an evolved package of incentives and regulatory benefits is driving growth in the manufacture of generic medicines. Incentives and other conditions favour and incentivise the setting up of R&D and innovative operations.
KPMG’s Pharmaceutical industry practice advises clients with critical business and industry issues, including:
- · enterprise risk management
- · research and development tax concessions
- · sales and marketing compliance
- · intellectual property and contract governance
- · transfer pricing
- · cross-border financing and tax planning
- · mergers, acquisitions and asset disposal
- · market entry and expansion
KPMG’s Pharmaceuticals industry advisers bring high-level technical capabilities and deep industry experience to every engagement. They are supported by KPMG’s global resources, collaborative knowledge sharing systems and industry insight programs.